We are live on
!
Find out more
WVP
Worth Venture Partners Portfolio holdings
AUM
$31.6M
1-Year Est. Return
28.5%
This Fund
S&P 500
This Quarter
Est. Return
+2.65%
1 Year Est. Return
+28.5%
3 Year Est. Return
+102.5%
5 Year Est. Return
+128.77%
10 Year Est. Return
–
AUM
$115M
AUM Growth
-$677K
(-0.58%)
Cap. Flow
-$15.8M
Cap. Flow
% of AUM
-13.74%
Top 10 Holdings %
Top 10 Hldgs %
55.42%
Holding
157
New
40
Increased
38
Reduced
31
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTC Therapeutics
PTCT
|
+$1.3M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$605K |
| 3 |
NetEase
NTES
|
+$589K |
| 4 |
Canadian Pacific Kansas City
CP
|
+$531K |
| 5 |
OTIC
Otonomy, Inc.
OTIC
|
+$432K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arista Networks
ANET
|
+$1.9M |
| 2 |
VGR
Vector Group Ltd.
VGR
|
+$774K |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$690K |
| 4 |
Silicom
SILC
|
+$367K |
| 5 |
Mastercard
MA
|
+$361K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 6.64% |
| 2 | Consumer Discretionary | 4.92% |
| 3 | Communication Services | 4.55% |
| 4 | Healthcare | 3.41% |
| 5 | Real Estate | 2.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BBBY
76
Bed Bath & Beyond
BBBY
$512M
| $216K | 0.19% |
+9,682
| New | +$146K |
|
77
CGI
GIB
$14.5B
| $213K | 0.18% |
4,109
-220
| -5% | -$11.3K |
|
78
Owens Corning
OC
$11.6B
| $213K | 0.18% |
+2,750
| New | +$192K |
|
79
Steven Madden
SHOO
$3.18B
| $205K | 0.18% |
+7,095
| New | +$195K |
|
|
FNSR
80
DELISTED
Finisar Corp
FNSR
| $198K | 0.17% |
+8,966
| New | +$220K |
|
|
TAST
81
DELISTED
Carrols Restaurant Group, Inc.
TAST
| $188K | 0.16% |
17,275
+690
| +4% | +$8.01K |
|
82
Ovintiv
OVV
$16.6B
| $184K | 0.16% |
3,130
+34
| +1% | +$1.66K |
|
83
Lipocine
LPCN
$17.6M
| $171K | 0.15% |
2,538
+1,174
| +86% | +$84.9K |
|
84
Teva Pharmaceuticals
TEVA
$36.2B
| $159K | 0.14% |
+9,020
| New | +$203K |
|
85
Nabors Industries
NBR
$1.16B
| $142K | 0.12% |
+351
| New | +$128K |
|
|
OTIC
86
DELISTED
Otonomy, Inc.
OTIC
| $104K | 0.09% |
+32,075
| New | +$432K |
|
|
ZGNX
87
CALL
DELISTED
Zogenix, Inc.
ZGNX
| $98K | 0.09% |
15,000
+9,700
| +183% | +$132K |
|
|
88
PUT
Lipocine
LPCN
$17.6M
| $91K | 0.08% |
2,782
+1,411
| +103% | +$102K |
|
89
Kinross Gold
KGC
$28.6B
| $85K | 0.07% |
+20,047
| New | +$85.7K |
|
|
IMMU
90
PUT
DELISTED
Immunomedics Inc
IMMU
| $82K | 0.07% |
67,900
+11,100
| +20% | +$111K |
|
|
AIMT
91
CALL
DELISTED
Aimmune Therapeutics
AIMT
| $75K | 0.07% |
+15,300
| New | +$330K |
|
92
NXP Semiconductors
NXPI
$67.6B
| $61K | 0.05% |
+542
| New | +$60.5K |
|
|
BBBY
93
PUT
Bed Bath & Beyond
BBBY
$512M
| $58K | 0.05% |
+99,692
| New | +$1.5M |
|
|
94
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$781B
| $49K | 0.04% |
+107,600
| New | +$26.5M |
|
|
LCI
95
PUT
DELISTED
Lannett Company, Inc.
LCI
| $43K | 0.04% |
+10,825
| New | +$795K |
|
|
DERM
96
PUT
DELISTED
Dermira, Inc.
DERM
| $41K | 0.04% |
+13,500
| New | +$353K |
|
97
CALL
Bristol-Myers Squibb
BMY
$128B
| $39K | 0.03% |
+43,000
| New | +$2.51M |
|
|
TGA
98
DELISTED
Transglobe Energy Corp
TGA
| $30K | 0.03% |
21,030
| – | – |
|
|
99
CALL
NXP Semiconductors
NXPI
$67.6B
| $20K | 0.02% |
37,300
+31,200
| +511% | +$3.48M |
|
100
PUT
ANI Pharmaceuticals
ANIP
$1.78B
| $18K | 0.02% |
19,700
+3,000
| +18% | +$143K |
|
Similar funds
VL
WTG
QCA
SP
OGC
PE
RL
AIIC
Worth Venture Partners's Q3 2017 Portfolio in Review
As of Q3 2017, Worth Venture Partners held 157 positions worth $115M, down 0.58% from $116M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Worth Venture Partners withdrew a net $15.8M in Q3 2017, closing 26 positions and reducing 31 holdings. Its most notable exit was Arista Networks, an estimated $1.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 6.6% of assets, down from 8% a quarter earlier, followed by Consumer Discretionary and Communication Services.
Against the trend, Worth Venture Partners opened a new position in PTC Therapeutics worth $1.32M.
- Worth Venture Partners's largest Q3 2017 buy was PTC Therapeutics: 66,196 shares worth $1.32M.
- Worth Venture Partners added most to NetEase in Q3 2017, an estimated $589K increase.
- Worth Venture Partners's biggest Q3 2017 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $690K.
- Worth Venture Partners fully exited Arista Networks in Q3 2017, selling an estimated $1.9M.
- Worth Venture Partners's ten largest holdings make up 55% of its $115M portfolio in Q3 2017.
- Worth Venture Partners opened 40 new positions and closed 26 in Q3 2017.
- Worth Venture Partners's portfolio value fell 0.58% quarter-over-quarter to $115M.
Based on Worth Venture Partners's 13F filing for Q3 2017, filed 7 Nov 2017.